We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Addition of Auricular Acupoint Stimulation to 0.01% Atropine for Myopia: 12-Month Results from a Randomized Trial.
- Authors
Kong, Xiehe; Yang, Guang; Chen, Zhi; Han, Rong; Zhao, Yue; Zeng, Li; Guo, Xiaocong; Shi, Zheng; Zhang, Dan; Yang, Yanting; Liu, Jie; Zhou, Xingtao; Ma, Xiaopeng
- Abstract
Introduction: A previous 6-month report showed that adjunctive auricular acupoint stimulation (AAS) slowed myopia progression compared with 0.01% atropine (0.01% A) alone. This 12-month report was to determine whether the antimyopic effect of AAS, when added to 0.01% A, continued beyond treatment cessation, and explore the mode of action of AAS from the accommodative response. Design and Interventions: One hundred four children were randomly assigned to either a 0.01% A group or a 0.01% A + AAS group. Participants in the 0.01% A + AAS group received AAS in addition to 0.01% A for 6 months, and then kept using 0.01% A for the following 6 months. Participants in the 0.01% A group only used 0.01% A. The primary outcome was the difference in the mean cycloplegic spherical equivalent refraction (SER) from the baseline to the 12-month visit. Secondary outcomes included axial length (AL) and accommodative lag assessments. Results: The adjusted mean change from baseline to month 12 in the SER was −0.62 D for 0.01% A and −0.46 D for 0.01% A + AAS (difference, 0.16 D; p = 0.01), with a respective mean increase of 0.37 and 0.31 mm in AL (difference, −0.05 mm; p = 0.05). For the 5D near target, there was a reduction in the accommodative lag in children receiving add-on AAS relative to 0.01% A alone at 1 and 6 months (both p = 0.002). Conclusions: AAS treatment produced additional benefits >0.01% A in slowing myopia progression over the 12-month period, where the efficacy was sustained after the cessation of AAS. An effect of add-on AAS on reducing accommodative lag in response to 5D stimulus was found, but its role in mediating therapeutic response remained unclear. Chinese Clinical Trial Registry number: ChiCTR1900021316
- Subjects
CHINA; MYOPIA treatment; DISEASE progression; STATISTICS; MYOPIA; INTRAOCULAR pressure; CONFIDENCE intervals; ATROPINE; ACUPUNCTURE; MANN Whitney U Test; EAR; TREATMENT effectiveness; RANDOMIZED controlled trials; T-test (Statistics); RESEARCH funding; DESCRIPTIVE statistics; BLIND experiment; COMBINED modality therapy; STATISTICAL sampling; DATA analysis; DATA analysis software; EVALUATION; CHILDREN
- Publication
Journal of Integrative & Complementary Medicine, 2023, Vol 29, Issue 9, p574
- ISSN
2768-3605
- Publication type
Article
- DOI
10.1089/jicm.2022.0769